Lyell Immunopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LYEL research report →
Range $34 – $45
Price Chart
About the company
Lyell Immunopharma, Inc. , a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
- CEO
- Lynn Seely
- IPO
- 2021
- Employees
- 161
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on LYEL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $339.28M
- P/E
- -0.86
- PEG
- 0.01
- P/S
- 22258.13
- P/B
- 1.72
- EV/EBITDA
- -1.12
- Div Yield
- 0.00%
- Gross Margin
- -15446.67%
- Op Margin
- -1354006.67%
- Net Margin
- -1701066.67%
- ROE
- -107.62%
- ROIC
- -89.24%
Latest fiscal year · YoY change
- Revenue
- $36.00K-41.0%
- Gross Profit
- $-11,503,000-18957.4%
- Op Income
- $-203,774,000
- Net Income
- $-274,448,000+20.0%
- EPS
- $-16.06-1126.0%
- OCF Growth
- +7.6%
- FCF Growth
- +7.4%
- 52W High
- $45.00
- 52W Low
- $7.20
- 50D MA
- $11.08
- 200D MA
- $16.11
- Beta
- -0.07
- RSI (14)
- 55
- Avg Volume
- 174.76K
No earnings-call transcripts are available for LYEL yet.
- Free Float
- 59.7%
- Shares Outstanding
- 24.59M
- Float Shares
- 14.67M
of shares held by institutions
91 13F filers
Buy/sell ratio 0.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Arch Venture Management, LLC | 3.25M | 0 |
| Gsk PLC | 1.51M | 0 |
| Vanguard Group Inc | 826.43K | ▲ 47.43K |
| Blackrock, Inc. | 799.06K | ▲ 74.72K |
| Orland Properties Ltd | 754.70K | 0 |
| Vanguard Capital Management LLC | 748.85K | ▼ 37.93K |
| Almitas Capital LLC | 581.41K | ▲ 3.60K |
| Foresite Capital Management V, LLC | 476.39K | ▼ 692 |
| Millennium Management LLC | 367.47K | ▼ 91.43K |
| Opaleye Management Inc. | 344.02K | ▲ 264.93K |
| Venbio Partners LLC | 337.70K | 0 |
| Alphabet Inc. | 293.26K | 0 |
Held by 142 ETFs
Biggest fund positions in LYEL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | Lee Gary K. | sell | 129 |
| Nov 10, 26 | Hill Stephen J. | sell | 88 |
| Nov 10, 26 | Seely Lynn | sell | 545 |
| Nov 10, 26 | Bulis Veronica Sanchez | sell | 416 |
| Nov 4, 26 | ARCH Venture Partners IX, LLC | buy | 2,321,262 |
| Nov 4, 26 | ARCH Venture Fund XIII, L.P. | buy | 2,321,262 |
| Oct 12, 26 | Aguirre Jarrad Mattieu | sell | 422 |
| Sep 10, 26 | Shook David | sell | 500 |
| Sep 10, 26 | Aguirre Jarrad Mattieu | other | 47,500 |
| Aug 31, 26 | Aguirre Jarrad Mattieu | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LYEL coverage
Recent articles, reports, and earnings notes.
No research on LYEL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LYEL report →Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High?
zacks.com · Nov 16
Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 11
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy
marketbeat.com · Nov 6
Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding Boost
seekingalpha.com · Nov 5
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
globenewswire.com · Nov 4
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
globenewswire.com · Nov 4
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
globenewswire.com · Nov 4
Lyell Immunopharma To Participate in November Investor Events
globenewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.